3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
60
Neoplasm Metastasis
5
Prostate Cancer Metastatic
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Adenocarcinoma
3
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Diseases
1
PSA Level Greater Than 0.03
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Interventions
gedatolisib
1
gallium 68 PSMA-11
1
darolutamide
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Genital Diseases, Male
×
Androgen Antagonists
×
1 year
×
Clear all
No trials found.